Kinase inhibitors for CNS diseases: an analysis of the recent patent literature

Federica Amigoni, Elena Legnaghi, Paolo Pevarello

Research output: Contribution to journalArticlepeer-review


Protein kinases (PKs), as members of an important target class in current pharmaceutical research, have been mostly exploited so far in therapeutic areas such as oncology and inflammation. However, basic research on some PKs as key components of molecular mechanisms underlying neurodegeneration and neuroprotection may translate into new medicines for CNS diseases in the next few years. This review is an account of recent patents dealing with kinase inhibitors primarily designed for CNS indications. CNS-directed patents on kinase modulators published after 2008 were surveyed using SciFinder(®) and public patent search engines. Some PK targets, such as GSK-3β, CDK5, ROCK and p38α MAPK, continue to attract interest even though a clinical proof-of-concept is yet to be attained in a CNS setting. Less established PKs such as LRRK2, MLK, PAK and DAPK-1 hold promise as valuable targets of the future.

Original languageEnglish
Pages (from-to)177-192
Number of pages16
JournalPharmaceutical patent analyst
Issue number2
Publication statusPublished - May 1 2012

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Kinase inhibitors for CNS diseases: an analysis of the recent patent literature'. Together they form a unique fingerprint.

Cite this